US Stock MarketDetailed Quotes

FATE Fate Therapeutics

Watchlist

4.270
-0.040-0.93%

Close Jul 19 16:00 ET

486.06MMarket Cap-2223P/E (TTM)

Fate Therapeutics Stock Forum

Jaguar8

May 29 15:04

NEWS

$Fate Therapeutics(FATE.US)$
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...

Trytosaveabit

May 9 07:35

Update

$Fate Therapeutics(FATE.US)$ Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy

Jaguar8

May 9 07:33

$Fate Therapeutics(FATE.US)$
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Trytosaveabit

Mar 19 07:45

$Fate Therapeutics(FATE.US)$ Press Release: Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Dow Jones· 1 min ago

Moomoo AI

Feb 29 05:02

Analysts downgrade revenue estimates for next year and reduce loss estimates. The company's revenue is expected to decline by 92% annually by end of 2024, a shift from historical growth of 47% over the last five years. Fate Therapeutics is expected to lag the wider industry.

US$7.53 - That's What Analysts Think Fate Therapeutics, Inc. (NASDAQ:FATE) Is Worth After These Results

Moomoo AI

Dec 19, 2023 13:53

Fate Therapeutics' P/S ratio aligns with peers due to predicted revenue drop in following years. Given forecasted revenue slide and below par industry growth, future share price gains may be minimal. It's vital to consider the company's future prospects and not just its P/S ratio when deciding to sell stock.